

CITATION REPORT

List of articles citing

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

DOI: 10.1161/01.hyp.0000123072.34629.57
Hypertension, 2004, 43, 993-1002.

Source: <https://exaly.com/paper-pdf/36656899/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
971	.		
970	Telmisartan is a potent target for prevention and treatment in human prostate cancer. 1994 , 20, 295		4
969	Telmisartan - killing two birds with one stone. 2004 , 5, 2397-400		18
968	Two for the price of one. 2004 , 3, 475-475		1
967	[Hypertension and metabolic syndrome]. 2004 , 123, 707-11		6
966	Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. 2004 , 64, 2537-65		201
965	An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. 2004 , 576, 492-7		82
964	Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. 2004 , 30, 487-96		212
963	Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. 2004 , 30, 498-505		132
962	VALUE: to the heart of the matter. 2004 , 22, 1431-4		7
961	Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. 2004 , 22, 2253-61		146
960	[Metabolic syndrome: which definition for what treatment(s)?]. 2005 , 21, 1045-53		10
959	The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. 2005 , 23, S9-S17		138
958	Kidney disease and the metabolic syndrome. 2005 , 330, 319-25		22
957	Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. 2005 , 54, 3442-52		248
956	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. 2005 , S57-65		306
955	Review article: the metabolic syndrome and non-alcoholic fatty liver disease. 2005 , 22 Suppl 2, 31-6		44

954	The Third International Symposium on Obesity and Hypertension ISOH'03: 'Genetics and Molecular Mechanisms' (October 23-25, 2003, Berlin Germany). 2005 , 29, 727-34	1
953	Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. 2005 , 19, 923-31	43
952	Hipertensi3n arterial y riesgo cardiovascular en el a3o 2004. 2005 , 5, 24A-34A	
951	Prevenci3n y tratamiento del s3ndrome metab3lico. 2005 , 5, 46D-52D	
950	Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. 2005 , 45, 866-74	74
949	[Blood pressure independent effects of antihypertensive agents]. 2005 , 46, 548-56	2
948	ADPKD: molecular characterization and quest for treatment. 2005 , 9, 282-291	11
947	Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. 2005 , 42 Suppl 1, S9-16	78
946	Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers. 2005 , 42 Suppl 1, S26-32	27
945	Do angiotensin II antagonists provide benefits beyond blood pressure reduction?. 2005 , 22, 117-36	5
944	Insulin resistance and the endothelium. 2005 , 5, 246-53	23
943	PPAR ligands: potential therapies for metabolic syndrome. 2005 , 5, 45-52	44
942	Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. 2005 , 7, 240-3	24
941	Antihypertensive treatment and new-onset diabetes mellitus. 2005 , 7, 298-303	16
940	Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice. 2005 , 7, 314-22	20
939	Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. 2005 , 4, 6	144
938	Why Less Diabetes with Blockade of the Renin-Angiotensin System?. 2005 , 16, 567-573	5
937	Angiotensin II and the endothelium: diverse signals and effects. <i>Hypertension</i> , 2005 , 45, 163-9	8.5 173

936	Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. 2005 , 112, 1798-805		71
935	Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. 2005 , 14, 196-209		59
934	PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. <i>Hypertension</i> , 2005 , 46, 137-43	8.5	240
933	Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. 2005 , 28, 757-8		95
932	Edema and Congestive Heart Failure from Thiazolidone Insulin Sensitizers Excess Sodium Reabsorption in the Collecting Duct. 2005 , 16, 3139-3142		1
931	Telmisartan: from lowering blood pressure to end-organ protection. 2005 , 1, 7-15		4
930	Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. 2005 , 28, 498		46
929	Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. 2005 , 280, 23653-9		81
928	Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. 2005 , 10, 729-45		7
927	A new transgenic rat model of hepatic steatosis and the metabolic syndrome. <i>Hypertension</i> , 2005 , 45, 1004-11	8.5	34
926	Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. 2005 , 20, 2670-80		70
925	Telmisartan/hydrochlorothiazide: a new fixed dose combination. 2005 , 3, 375-86		11
924	Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. 2005 , 182, 57-69		44
923	Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications. 2005 , 5, 389-98		13
922	Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. 2005 , 64, 476-8		78
921	Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. 2005 , 328, 484-90		35
920	Rein et glitazones. 2005 , 66, 81-90		1
919	Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome. 2006 , 5, 89-99		15

918	Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan. 2006 , 4, 615-29	21
917	Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis. 2006 , 20, 121-35	13
916	The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines?. 2006 , 6, 139-47	15
915	New Onset of Type 2 Diabetes Mellitus during Antihypertensive Therapy. 2006 , 13, 29-36	
914	Selective Peroxisome Proliferator-Activated Receptor- γ Modulation in the Treatment of Hypertension and Metabolic Syndrome. 2006 , 13, 81-84	
913	Telmisartan. 2006 , 13, 85-94	8
912	Obesity and the renin- angiotensin-aldosterone system. 2006 , 1, 255-264	3
911	Hipertensi3 arterial y s3ndrome metab3lico. 2006 , 32, 73-83	0
910	Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. 2006 , 72, 184-90	84
909	Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. 2006 , 186, 402-10	103
908	Effect of antihypertensive agents on the development of type 2 diabetes mellitus. 2006 , 81, 796-806	47
907	Telmisartan: a review of its use in the management of hypertension. 2006 , 66, 51-83	105
906	[Role of angiotensin II receptor antagonists in the treatment of metabolic syndrome]. 2006 , 206, 284-8	0
905	Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. 2006 , 17, S206-12	84
904	Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists. 2006 , 49, 4072-84	38
903	The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. 2006 , 55, 1149-54	72
902	Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. 2006 , 55, 1159-64	85
901	Hypolipidemic therapy for the metabolic syndrome. 2006 , 53, 492-500	23

900	Nuclear Hormone Receptor Modulators for the Treatment of Diabetes and Dyslipidemia. 2006 , 41, 99-126	15
899	The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. 2006 , 29, 957-61	60
898	New treatment strategies for patients with hypertension and insulin resistance. 2006 , 119, S24-30	57
897	Heart and kidney: fatal twins?. 2006 , 119, S31-9	34
896	Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. 2006 , 374, 129-34	18
895	Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. 2006 , 38, 766-81	51
894	Angiotensin receptor blockers: new considerations in their mechanism of action. 2006 , 8, 381-5	8
893	The pleiotropic effects of angiotensin receptor blockers. 2006 , 8, 261-8	44
892	Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. 2006 , 66, 118-20	7
891	Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. 2006 , 47, 5545-52	96
890	Role of the renin-angiotensin- aldosterone system in the metabolic syndrome. 2006 , 151, 122-134	30
889	Downregulation of peroxisome proliferator activated receptor gamma co-activator 1alpha in diabetic rats. 2006 , 47, 901-10	12
888	Telmisartan/hydrochlorothiazide in the treatment of hypertension. 2006 , 2, 395-408	2
887	Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 733-749	3
886	Angiotensin-receptor blockers for renal protection in Type 2 diabetes. 2006 , 2, 295-301	
885	The tissue renin-angiotensin system and intracellular signalling. 2006 , 15, 8-13	47
884	Prospects for the prevention of stroke. 2006 , 24, S3-9	7
883	Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. 2006 , 24, 1809-16	71

882	Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases. 2006 , 1, 139-46	5
881	Current World Literature. 2006 , 13, 212-236	
880	[Diabetes and the metabolic syndrome]. 2006 , 128, 133-40	
879	Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. 2006 , 3, 1	107
878	Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding. 2006 , 65, 824-42	24
877	Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. 2006 , 20, 860-6	27
876	Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. 2006 , 70, 1717-24	130
875	Human genetics of adiponectin in the metabolic syndrome. 2006 , 84, 112-21	86
874	Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. 2006 , 49, 3094-9	106
873	Metabolic effects of telmisartan in spontaneously hypertensive rats. 2006 , 373, 264-70	11
872	Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. 2006 , 45, 154-62	115
871	Activation of PPAR by Sartans. 2006 , 67, 579-581	1
870	New generation angiotensin II type 1 receptor antagonists that selectively modulate peroxisome proliferator-activated receptor- γ 2006 , 67, 687-697	4
869	Functional and structural renal changes in the early stages of obesity. 2006 , 151, 135-150	11
868	Telmisartan: the ACE of ARBs?. <i>Hypertension</i> , 2006 , 47, 822-3	8.5 19
867	Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome. 2006 , 2, 151-159	
866	Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management. 2006 , 7, 2505-20	2
865	Telmisartan, its potential therapeutic implications in cardiometabolic disorders. 2006 , 1, 79-83	2

864	Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. 2006 , 26, 2252-9		105
863	Regressing Left Ventricular Hypertrophy: The Role of Telmisartan and Other ARBs. 2006 , 2, 187-192		
862	Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. 2006 , 6, 835-44		15
861	Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. <i>Hypertension</i> , 2006 , 48, 51-7	8.5	106
860	The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. 2006 , 7, 243-6		24
859	Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. <i>Hypertension</i> , 2006 , 47, 586-9	8.5	75
858	A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. 2006 , 20, 809-30		137
857	Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. 2006 , 29, 195-201		54
856	Potential protective effects of telmisartan on renal function deterioration. 2006 , 7, 185-91		11
855	The Diabetic Kidney. 2006 ,		1
854	Treatment of arterial hypertension in obese patients. 2006 , 151, 230-242		5
853	Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. <i>Hypertension</i> , 2006 , 47, 1003-9	8.5	129
852	Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials. 2007 , 5, 451-61		4
851	Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 293, E91-5	6	31
850	Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. 2007 , 293, H1327-33		40
849	Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects. <i>PPAR Research</i> , 2007 , 2007, 32696	4.3	81
848	Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. 2007 , 7, 463-9		66
847	Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. 2007 , 30, 49-53		40

846	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. 2007 , 11, 191-205		21
845	Ceramide and adenosine 5'-monophosphate-activated protein kinase are two novel regulators of 11beta-hydroxysteroid dehydrogenase type 1 expression and activity in cultured preadipocytes. 2007 , 148, 5268-77		24
844	Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats. 2007 , 30, 1231-7		23
843	Potential utility of combination therapy with nateglinide and telmisartan for metabolic derangements in Zucker Fatty rats. 2007 , 39, 889-93		6
842	Pharmacoeconomics and quality of life analysis of telmisartan in hypertension treatment. 2007 , 7, 435-44		
841	Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism. 2007 , 29, 419-26		8
840	Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. 2007 , 322, 1051-8		86
839	Molecular genetics of experimental hypertension and the metabolic syndrome: from gene pathways to new therapies. <i>Hypertension</i> , 2007 , 49, 941-52	8.5	39
838	Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes. 2007 , 8, 587-96		10
837	Angiotensin II type 1 receptor gene regulation: transcriptional and posttranscriptional mechanisms. <i>Hypertension</i> , 2007 , 49, 953-61	8.5	31
836	Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. 2007 , 46, 1331-6		49
835	Cilnidipine and Telmisartan Similarly Improves Vascular Damage in Hypertensive Patients. 2007 , 1, CMC.S353		2
834	Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma. <i>Journal of Atherosclerosis and Thrombosis</i> , 2007 , 14, 133-41	4	52
833	Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. 2007 , 25, 841-8		80
832	Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. 2007 , 25, 1643-9		23
831	Peroxynitrite is Involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats. 2007 , 50, 677-85		34
830	Vascular effects of PPARgamma activators - from bench to bedside. 2007 , 46, 283-96		19
829	Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. 2007 , 20, 431-6		50

828	The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. 2007 , 20, 565-72	40
827	Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. 2007 , 1771, 1094-107	62
826	Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma activation. 2007 , 356, 1024-30	32
825	Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. 2007 , 364, 801-7	45
824	Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?. 2007 , 7, 140-5	36
823	Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. 2007 , 77, 210-4	50
822	Renin-angiotensin system and cardiovascular risk. 2007 , 369, 1208-19	507
821	Tratamiento de enfermedades metabólicas mediante la modulación del PPAR α 2007 , 19, 191-210	
820	Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus. 2007 , 56, 217-23	19
819	Interaction of endothelial nitric oxide and angiotensin in the circulation. 2007 , 59, 54-87	56
818	Telmisartan-enhanced hypercholesterolaemic serum-induced vascular endothelial growth factor expression in immortalized human umbilical vascular endothelial cells. 2007 , 67, 619-31	3
817	Alpha-lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome. 2007 , 16, 291-302	32
816	Metabolic syndrome and cardiovascular disease. 2007 , 44, 232-63	69
815	Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. 2007 , 292, C82-97	1369
814	Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. 2007 , 30, 1205-10	46
813	Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. 2007 , 56, 1470-7	22
812	BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan. <i>Clinical Drug Investigation</i> , 2007 , 27, 783-96	3.2 6
811	Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. 2007 , 20, 1305-11	22

810	Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1). 2007 , 48, 637-47		13
809	Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 293, E1465-78	6	67
808	Peroxisome Proliferator-Activated Receptors and the Endothelium. 796-805		
807	De novo nonalcoholic fatty liver disease after liver transplantation. 2007 , 13, 844-7		140
806	Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. 2007 , 6, 12		73
805	Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study. 2007 , 6, 36		34
804	Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. 2007 , 67, 924-32		38
803	ABNORMALITIES OF NITRIC OXIDE-MEDIATED VASORELAXATION IN A RAT MODEL OF METABOLIC SYNDROME: INVOLVEMENT OF PEROXYNITRITE FORMATION. 2007 , 34, S23-S25		
802	The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus. 2007 , 9, 617-29		8
801	Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats. <i>European Journal of Pharmacology</i> , 2007 , 564, 131-7	5-3	7
800	WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats. <i>European Journal of Pharmacology</i> , 2007 , 577, 100-8	5-3	22
799	Prevention of stroke in patients with hypertension. 2007 , 100, 17J-24J		51
798	Rationale for double renin-angiotensin-aldosterone system blockade. 2007 , 100, 25J-31J		44
797	Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. 2007 , 100, 1625-9		35
796	Efectos pleiotrpicos de telmisartn en el paciente diabtico. 2007 , 7, 23A-30A		
795	Hipertensi arterial y dislipemia asociadas a diabetes mellitus. Papel de los PPAR. Enfoque teraputico. 2007 , 7, 20H-28H		
794	Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. 2007 , 24, 146-53		43
793	Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. 2007 , 52, 3455-64		62

792	Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients. 2007 , 21, 317-8	11
791	[Antihypertensive and metabolic effects of telmisartan in patients with the metabolic syndrome in primary care--a field study]. 2007 , 157, 223-7	2
790	The effects of simultaneous administration of dietary conjugated linoleic acid and telmisartan on cardiovascular risks in rats. 2007 , 42, 855-64	12
789	Antihypertensive agents, insulin sensitivity, and new-onset diabetes. 2007 , 7, 191-9	40
788	The metabolic syndrome in hypertension: diagnostic and therapeutic implications. 2007 , 9, 305-13	6
787	Management of arterial hypertension in obese patients. 2007 , 9, 491-7	15
786	Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer. 2007 , 1, 3-13	1
785	Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. 2008 , 314, 123-31	40
784	Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma. 2008 , 28, 543-8	14
783	Pharmacologic modulation of ACE2 expression. 2008 , 10, 410-4	50
782	Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model. 2008 , 7, 3	11
781	Method for comparing the structures of protein ligand-binding sites and application for predicting protein-drug interactions. 2008 , 72, 367-81	45
780	Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. 2008 , 21, 576-81	86
779	Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. 2008 , 15, 19-26	25
778	Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. 2008 , 1208, 225-33	37
777	Efectos metabólicos del tratamiento con antagonistas de los receptores de la angiotensina II. 2008 , 8, 22E-29E	1
776	Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. 2008 , 57, 1473-8	51
775	Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. 2008 , 9, 15-31	95

774	Candesartan and renal protection: more than blocking angiotensin type 1 receptor?. 2008 , 74, 1112-4	4
773	Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. 2008 , 8, 247-53	43
772	Protection of pancreatic beta-cells: is it feasible?. 2008 , 18, 74-83	62
771	Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium. 2008 , 373, 253-7	24
770	Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. 2008 , 375, 446-9	109
769	The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. 2008 , 82, 127-31	31
768	Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. 2008 , 74, 1128-38	63
767	Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. 2008 , 199, 295-303	57
766	Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. 2008 , 2, 239-66	15
765	Does it matter how blood pressure is lowered in patients with metabolic risk factors?. 2008 , 2, S23-9	7
764	Preventing stroke in hypertensive patients at risk. 2008 , 2, S38-45	4
763	Eficacia de una estrategia basada en ARA-II en el tratamiento de pacientes hipertensos con s̈ndrome metab̈lico. 2008 , 25, 141-146	
762	FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. 2008 , 77, 560-9	37
761	Eficacia de una estrategia basada en ARA-II en el tratamiento de pacientes hipertensos con s̈ndrome metab̈lico. 2008 , 25, 141-146	
760	Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. 2008 , 6, 343-68	340
759	Telmisartan as a metabolic sartin for targeting vascular failure. 2008 , 9, 1397-406	10
758	Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. 2008 , 60, 311-57	288
757	Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. <i>Hypertension</i> , 2008 , 51, 696-703	8.5 62

756	Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system. <i>Hypertension</i> , 2008 , 51, 1442-8	8.5	19
755	Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor. 2008 , 49, 4370-6		27
754	Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention. 2008 , 26, 106-12		14
753	PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies. <i>PPAR Research</i> , 2008 , 2008, 164273	4.3	20
752	Clinical efficacy of a new angiotensin II type 1 receptor blocker, prazosin, in hypertensive patients. 2008 , 31, 281-7		4
751	Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. 2008 , 31, 7-13		57
750	Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. 2008 , 6, 289-303		10
749	Renin-angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center. 2008 , 74, 851-3		7
748	Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. <i>Hypertension</i> , 2008 , 51, 259-66	8.5	17
747	Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. 2008 , 57, 1405-13		69
746	Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. 2008 , 21, 852-9		23
745	Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. 2008 , 21, 1330-6		22
744	Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI). 2008 , 36, 1094-102		18
743	Adiponectin, cardiovascular function, and hypertension. <i>Hypertension</i> , 2008 , 51, 8-14	8.5	193
742	Treatment options for nonalcoholic Fatty liver disease. 2008 , 1, 173-89		10
741	Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats. 2008 , 31, 135-40		20
740	Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. 2008 , 31, 601-6		40
739	Beyond the classic angiotensin-receptor-blocker profile. 2008 , 5 Suppl 1, S19-26		26

738	Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats. 2008 , 31, 525-33		14
737	Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy. 2008 , 31, 615-22		24
736	Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients. 2008 , 40, 640-4		14
735	Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. 2008 , 31, 161-8		21
734	Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. 2008 , 31, 1611-8		29
733	Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. <i>Hypertension</i> , 2008 , 52, 573-80	8.5	84
732	Eicosanoids and renal damage in cardiometabolic syndrome. 2008 , 4, 165-74		46
731	Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. 2008 , 31, 921-9		21
730	Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. 2008 , 6, 87-102		182
729	Inhibiting angiotensin type 1 receptors as a target for diabetes. 2008 , 12, 1257-63		25
728	Therapy for nonalcoholic fatty liver disease. 2008 , 42, 332-5		6
727	Pleiotropic effects of telmisartan: still more to come?. 2008 , 26, 854-6		8
726	Aegis against stroke and dementia by angiotensin type 1 receptor blockers: new beneficial aspects. 2008 , 31, 1-3		2
725	Differential response of vascular hepatocyte growth factor concentration and lipid accumulation between telmisartan and losartan in ApoE-deficient mice. 2008 , 1, 657-61		6
724	Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. 2008 , 26, 964-72		34
723	Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. 2008 , 26, 1209-15		29
722	PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?. 2008 , 8, 728-49		79
721	The metabolic syndrome in hypertension: European society of hypertension position statement. 2008 , 26, 1891-900		92

720	The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. 2008 , 15, 147-52		36
719	Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?. 2008 , 26, 973-80		30
718	Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. 2008 , 26, 2393-8		26
717	Effects of Telmisartan Compared with Valsartan on Plasma Adiponectin Levels and Arterial Stiffness in Patients with Type 2 Diabetes - A Pilot Study. 2008 , 32, 236		
716	Angiotensin receptor blockers and microalbuminuria in hypertensive patients with early (microalbuminuric) stage diabetic nephropathy. 2008 ,		
715	Peroxisome proliferator-activated receptors in diabetic nephropathy. <i>PPAR Research</i> , 2008 , 2008, 879523	4.3	7
714	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. <i>Vascular Health and Risk Management</i> , 2008 , 129	4.4	3
713	[A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists]. 2008 , 45, 428-33		6
712	Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension. 2009 , 50, 85-93		14
711	The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. 2009 , 39, 180-4		18
710	Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. 2009 , 50, 501-12		38
709	Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. 2009 , 50, 73-83		20
708	Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A(2) level in experimental stroke. 2009 , 26, 2355-64		20
707	Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients. 2009 , 31, 105-15		5
706	Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs. 2009 , 22, 1126-9		14
705	Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. <i>Hypertension</i> , 2009 , 54, 782-7	8.5	152
704	Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation. <i>Hypertension</i> , 2009 , 54, 1353-9	8.5	35
703	Telmisartan: a different angiotensin II receptor blocker protecting a different population?. 2009 , 37, 1662-79		44

702	Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling. 2009 , 82, 468-75		55
701	Beneficial effects of telmisartan in an HIV+ diabetic insulin-dependent patient. 2009 , 22, 853-7		3
700	AGTR1 as a therapeutic target in ER-positive and ERBB2-negative breast cancer cases. 2009 , 8, 3794-5		18
699	Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma. 2009 , 32, 765-9		34
698	Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation. <i>Hypertension</i> , 2009 , 54, 738-43	8.5	37
697	Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. 2009 , 296, F398-405		164
696	Mineralocorticoid receptor blockers and chronic kidney disease. 2009 , 4, 1685-91		23
695	Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta. <i>Hypertension</i> , 2009 , 53, 798-804	8.5	42
694	An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice. 2009 , 331, 1096-103		16
693	Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome?. <i>Hypertension</i> , 2009 , 54, 710-2	8.5	11
692	Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade. 2009 , 75, 685-92		28
691	A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. 2009 , 150, 862-70		29
690	Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells. 2010 , 14, 1645-56		24
689	Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease. 2009 , 31, 2113-25		11
688	Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. 2009 , 78, 951-8		87
687	Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats. <i>European Journal of Pharmacology</i> , 2009 , 605, 164-9	5.3	28
686	Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?. <i>European Journal of Pharmacology</i> , 2009 , 614, 146-52	5.3	23
685	Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction. <i>European Journal of Pharmacology</i> , 2009 , 619, 75-84	5.3	21

684	Characterization of new PPARgamma agonists: analysis of telmisartan's structural components. 2009 , 4, 445-56	36
683	Characterization of new PPARgamma agonists: benzimidazole derivatives - the importance of position 2. 2009 , 4, 1136-42	20
682	A mild and expedient one-pot synthesis of substituted benzimidazoles in water using a phase-transfer catalyst. 2009 , 140, 375-380	14
681	The role of peroxisome proliferator-activated receptor gamma in blood pressure regulation. 2009 , 11, 239-45	12
680	Design, synthesis, and docking studies of novel telmisartan-glitazone hybrid analogs for the treatment of metabolic syndrome. 2009 , 18, 589-610	9
679	Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake. 2009 , 23, 1316-25	49
678	Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. 2009 , 34, 683-92	11
677	Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). 2010 , 64, 160-8	5
676	Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. 2009 , 11, 757-69	14
675	Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. 2009 , 158, 771-8	38
674	Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. 2009 , 29, 988-96	64
673	Rapid determination of telmisartan in human plasma by HPLC using a monolithic column with fluorescence detection and its application to a bioequivalence study. 2009 , 877, 3729-33	27
672	The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly. 2009 , 49 Suppl 1, 95-101	6
671	Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. 2009 , 32, 604-10	10
670	Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. 2009 , 35, 392-7	27
669	Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. 2009 , 83, 117-8	12
668	Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amlodipine vs. ARB in atherosclerosis study). 2009 , 83, 50-3	22
667	Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. 2009 , 98, 192-7	79

666	Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. 2009 , 132, 114-20		15
665	Deletion of angiotensin II type I receptor reduces hepatic steatosis. 2009 , 50, 1226-35		46
664	Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism. 2009 , 464, 151-5		27
663	Next generation multifunctional angiotensin receptor blockers. 2009 , 32, 826-34		63
662	Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. 2009 , 93, 733-51		79
661	Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway. 2009 , 205, 376-84		67
660	Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging. 2009 , 27, 1892-9		23
659	Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. 2009 , 27, 2409-20		38
658	Benefits of the RAS blockade: clinical evidence before the ONTARGET study. 2009 , 27, S3-7		23
657	Telmisartan as a peroxisome proliferator-activated receptor- γ ligand is a new target in the treatment of human renal cell carcinoma. 2009 , 2, 193-8		22
656	Telmisartan increases the permeability of endothelial cells through zonula occludens-1. <i>Biological and Pharmaceutical Bulletin</i> , 2009 , 32, 416-20	2.3	12
655	Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats. 2009 , 111, 193-200		51
654	Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. 2009 , 15, 571-84		33
653	Are the pleiotropic effects of telmisartan clinically relevant?. 2009 , 15, 2815-32		22
652	Irbesartan and hydrochlorothiazide association in the treatment of hypertension. 2009 , 7, 120-36		2
651	Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. 2010 , 8, 189-97		31
650	Irbesartan: Second Generation of ARB as Metabosartan. 2010 , 6, 173-179		5
649	Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. 2010 , 28, 1730-7		51

648	Telmisartan inhibits human urological cancer cell growth through early apoptosis. 2010 , 1, 301-306	33
647	The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. 2010 , 49, 919-23	4
646	HIV protease inhibitors activate the adipocyte renin angiotensin system. 2010 , 15, 363-75	48
645	Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. 2010 , 119, 239-50	103
644	Open-label, Randomized Crossover Study Between Telmisartan and Valsartan on Improving Insulin Resistance and Adipocytokines in Nondiabetic Patients with Mild Hypertension. 2010 , 5, 165-74	1
643	Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. 2010 , 19, 489-512	44
642	Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. 2010 , 53, 1727-31	42
641	Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients. 2010 , 25, 195-202	16
640	Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril. 2010 , 25, 460-8	19
639	Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode. 2010 , 18, 5885-95	26
638	Differential susceptibility to epithelial-mesenchymal transition (EMT) of alveolar, bronchial and intestinal epithelial cells in vitro and the effect of angiotensin II receptor inhibition. 2010 , 342, 39-51	33
637	The effects of telmisartan on mechanical responses of left ventricular papillary muscle in rats with streptozotocin-induced diabetes mellitus. 2010 , 47 Suppl 1, 153-9	5
636	Regression of target organ damage in children and adolescents with primary hypertension. 2010 , 25, 2489-99	122
635	Drug synergism of antihypertensive action in combination of telmisartan with lercanidipine in spontaneous hypertensive rats. 2010 , 33, 1411-8	6
634	Comparative evaluation of angiotensin II receptor blockers on HOMA-R and adiponectin release in hypertensive patients with mild type 2 diabetes. 2010 , 1, 93-98	
633	Advances in pharmacologic modulation of nitric oxide in hypertension. 2010 , 12, 472-80	14
632	Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain. 2010 , 59, 25-32	13
631	Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. 2010 , 59, 1200-9	27

630	The effect of Telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells. <i>European Journal of Pharmacology</i> , 2010 , 628, 51-6	5-3	17
629	Ameliorative effects of telmisartan in diabetic rats with indomethacin-induced gastric ulceration. <i>European Journal of Pharmacology</i> , 2010 , 637, 162-70	5-3	21
628	Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells. <i>European Journal of Pharmacology</i> , 2010 , 649, 23-8	5-3	5
627	Telmisartan in high-risk cardiovascular patients. 2010 , 105, 36A-43A		2
626	Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. 2010 , 32, 492-505		41
625	Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. 2010 , 1340, 70-80		40
624	Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia. 2010 , 1353, 125-32		38
623	Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. 2010 , 185, 137-42		25
622	Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. 2010 , 12, 746-52		11
621	The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats. 2010 , 28, 58-65		10
620	Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. 2010 , 31, 150-61		58
619	1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPAR δ partial agonists. 2010 , 18, 8315-23		19
618	Synthesis and biological activities of novel indole derivatives as potent and selective PPAR γ modulators. 2010 , 20, 1399-404		41
617	PPAR γ activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. 2010 , 9, 64		44
616	Irbesartan treatment up-regulates hepatic expression of PPAR α and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia. 2010 , 160, 1796-807		22
615	Telmisartan improves morphologic and functional changes in both left ventricular myocardium and carotid arterial wall in patients with hypertension: assessment by tissue Doppler imaging and carotid ultrasonography. 2010 , 27, 864-72		14
614	Telmisartan and metabolic syndrome after heart transplantation. 2010 , 24, 36-9		1
613	Structural basis for the activation of peroxisome proliferator-activated receptor-gamma by telmisartan. 2010 ,		

612	New standards in hypertension and cardiovascular risk management: focus on telmisartan. <i>Vascular Health and Risk Management</i> , 2010 , 6, 113-33	4.4	30
611	Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. 2010 , 5, 403-16		15
610	Impact of telmisartan in modifying vascular risk. 2010 , 3, 81-9		1
609	Renovascular and renoprotective properties of telmisartan: clinical utility. 2010 , 3, 33-8		4
608	Losartan Inhibits Vascular Smooth Muscle Cell Proliferation through Activation of AMP-Activated Protein Kinase. 2010 , 14, 299-304		27
607	Nitric Oxide Asymmetric Dimethylarginine System in Endothelial Cell Senescence. 2010 , 483-511		1
606	Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals. 2010 , 3, 73-9		1
605	Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients. 2010 , 30, 66-71		7
604	Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. 2010 , 163, 573-83		12
603	Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. 2010 , 26, 477-81		23
602	Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. <i>Hypertension</i> , 2010 , 55, 869-79	8.5	88
601	Nephroprotective effect of telmisartan in rats with ischemia/reperfusion renal injury. 2010 , 85, 158-67		33
600	Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. <i>Hypertension</i> , 2010 , 55, 437-44	8.5	34
599	Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. 2010 , 33, 304-12		35
598	Nitro-oleic acid inhibits angiotensin II-induced hypertension. 2010 , 107, 540-8		96
597	Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment. 2010 , 12, 393-8		9
596	Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. 2010 , 41, 1798-806		101
595	Therapeutic Implications of PPARgamma in Cardiovascular Diseases. <i>PPAR Research</i> , 2010 , 2010,	4.3	9

594	Preparation, physicochemical characterization, dissolution and formulation studies of telmisartan cyclodextrin inclusion complexes. 2010 , 4, 52	12
593	Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results. 2010 , 8, 1509-17	6
592	Effect of losartan on vascular function in fructose-fed rats: the role of perivascular adipose tissue. 2010 , 32, 98-104	31
591	Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels. 2010 , 32, 21-8	5
590	Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts. 2010 , 86, 401-9	55
589	Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. 2010 , 25, 389-99	46
588	Substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonist: a review. 2010 , 10, 1366-84	29
587	Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. 2010 , 78, 1136-53	109
586	Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages. 2010 , 33, 831-5	43
585	Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome. 2010 , 4, e83-e162	9
584	Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome. 2010 , 53, 1076-85	28
583	eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. 2010 , 176, 619-29	45
582	Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury. 2010 , 32, 1088-94	14
581	Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance. 2010 , 139, 289-96	29
580	Current perspective of pathophysiological and interventional effects on endothelial progenitor cell biology: focus on PI3K/AKT/eNOS pathway. 2010 , 144, 350-66	77
579	The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice. <i>Biomedicine and Pharmacotherapy</i> , 2010 , 64, 712-7	7-5 24
578	Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats. 2010 , 47, 5-11	23
577	Candesartan attenuates fatty acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. 2010 , 90, 54-9	21

576	Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. 2010 , 21, 236-9	18
575	Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. 2010 , 396, 921-6	15
574	Effect of telmisartan on the expression of cardiac adiponectin and its receptor 1 in type 2 diabetic rats. 2011 , 63, 87-94	21
573	Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. 2010 , 6, 863-71	35
572	A small difference in the molecular structure of angiotensin II receptor blockers induces AT ₁ receptor-dependent and -independent beneficial effects. 2010 , 33, 1044-52	37
571	Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. 2010 , 33, 796-801	28
570	Applied Healthspan engineering. 2010 , 13, 265-80	7
569	Modulation of metabolic and cardiac dysfunctions by insulin sensitizers and angiotensin receptor blocker in rat model of type 2 diabetes mellitus. 2011 , 89, 216-26	9
568	Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats. 2011 , 12, 169-75	9
567	Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR- γ agonist action. 2011 , 45, 575-84	66
566	Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor- α activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A ₂ 2011 , 9, 217-23	3
565	Telmisartan suppresses food intake in mice via the melanocortin pathway. 2011 , 5, e79-e156	4
564	Telmisartan effectively improves insulin sensitivity in hypertensive patients with insulin resistance. 2011 , 5, e267-360	4
563	Endothelium-dependent vasomotor effects of telmisartan in isolated rat femoral arteries. 2011 , 63, 199-206	7
562	Telmisartan: a review of its use in cardiovascular disease prevention. 2011 , 71, 651-77	9
561	Adiponectin and hypertension. 2011 , 24, 263-9	93
560	Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor- α 2011 , 54, 4219-33	43
559	Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats. 2011 , 63, 956-66	38

558	Efecto del tratamiento con candesartan sobre los mecanismos y factores implicados en el desarrollo de la enfermedad cardiovascular asociada a sobrepeso y exceso de tejido adiposo visceral en la rata. 2011 , 23, 55-61	
557	The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance. 2011 , 94, 71-6	10
556	Irbesartan increased PPAR α activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. 2011 , 406, 123-6	20
555	Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT I receptor blockade. 2011 , 409, 275-9	29
554	Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor- β dependent activity. 2011 , 410, 508-13	29
553	Osteogenic differentiation of mesenchymal stem cells is preserved by partial, but not full peroxisome proliferator-activated receptor- β agonist. 2011 , 146, 109-10	1
552	Cardiac syndrome X: the pathophysiology should be expanded?. 2011 , 146, 110-1; author reply 111-2	2
551	Protective effect of telmisartan against cadmium-induced nephrotoxicity in mice. 2011 , 89, 29-35	30
550	Anti-inflammatory activity of telmisartan in rat models of experimentally-induced chronic inflammation: Comparative study with dexamethasone. 2011 , 19, 29-34	14
549	Combined use of calcium channel blockers and inhibitors of the renin-angiotensin system for treating hypertension. <i>Therapy: Open Access in Clinical Medicine</i> , 2011 , 8, 247-260	2
548	Telmisartan for the reduction of cardiovascular morbidity and mortality. 2011 , 4, 151-61	18
547	Telmisartan: just an antihypertensive agent? A literature review. 2011 , 12, 2719-35	34
546	Olmесartan severely weakened the development of NASH in an animal model of hypercholesterolemia. 2011 , 216, 97-102	14
545	SARTANS OF THE SECOND GENERATION: THERAPEUTIC POTENTIAL EXTENSION. 2011 , 7, 477-482	
544	Amelioration of chronic cyclosporine A-induced nephrotoxicity by telmisartan in rats. 2011 , 5, 500-505	2
543	Telmisartan inhibits the progression of cardiomyopathy in daunorubicin treated rats: the role of advanced glycation end products. 2011 , 255	1
542	Differential clinical profile of candesartan compared to other angiotensin receptor blockers. <i>Vascular Health and Risk Management</i> , 2011 , 7, 749-59	4-4 20
541	Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor α Activity and on Glucose Uptake by Thiazolidinediones. 2011 , 35, 340-7	20

540	Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2011 , 7, 605-22	4-4	21
539	Telmisartan and cardioprotection. <i>Vascular Health and Risk Management</i> , 2011 , 7, 677-83	4-4	9
538	Telmisartan versus valsartan in patients with hypertension: effects on cardiovascular, metabolic, and inflammatory parameters. 2011 , 41, 583-9		7
537	Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal function. 2011 , 6, e16794		38
536	Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR- γ 2011 , 9, 162-6		9
535	Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. 2011 , 29, 2476-83		47
534	The pleiotropic effects of ARB in vascular endothelial progenitor cells. 2011 , 9, 153-7		12
533	Pleiotropic effects of ARB on dyslipidemia. 2011 , 9, 129-35		10
532	Telmisartan improves insulin resistance in patients with low cytokine levels. 2011 , 59, 602-5		2
531	Role of peroxisome proliferator-activated receptor- γ in atherosclerosis: an update. 2011 , 75, 528-35		55
530	Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. 2011 , 16, 639-45		28
529	Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ 2011 , 116, 309-15		14
528	Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. 2011 , 29, 623-35		145
527	Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. 2011 , 13, 1123-9		34
526	Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan. 2011 , 36, 103-10		10
525	Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage. 2011 , 163, 1122-30		46
524	Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. 2011 , 91, 932-44		64
523	Angiotensin receptor blockers: pharmacology, efficacy, and safety. 2011 , 13, 677-86		58

522	Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR- γ /AMPK pathway. 2011 , 15, 1572-81		43
521	Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. 2011 , 58, 151-7		39
520	Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress. <i>European Journal of Pharmacology</i> , 2011 , 652, 126-35	5:3	20
519	Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes. <i>European Journal of Pharmacology</i> , 2011 , 660, 485-91	5:3	14
518	PPAR- δ and AMPK--advantageous targets for myocardial ischemia/reperfusion therapy. 2011 , 82, 195-200		58
517	Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. 2011 , 24, 816-21		22
516	Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension. 2011 , 34, 261-5		6
515	Pilot data on telmisartan short-term effects on glucose metabolism in the olfactory tract in Alzheimer's disease. 2011 , 1, 63-9		7
514	Comparative study of telmisartan tablets prepared via the wet granulation method and pritor \square prepared using the spray-drying method. 2011 , 34, 463-8		10
513	Pharmacophore-driven identification of PPAR δ agonists from natural sources. 2011 , 25, 107-16		38
512	Novel PPAR δ partial agonists with weak activity and no cytotoxicity; identified by a simple PPAR δ ligand screening system. 2011 , 358, 75-83		18
511	Telmisartan improves nonalcoholic steatohepatitis in medaka (<i>Oryzias latipes</i>) by reducing macrophage infiltration and fat accumulation. 2011 , 344, 125-34		31
510	Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure. 2011 , 383, 373-84		21
509	Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). 2011 , 28, 698-706		22
508	Differential effects of enalapril and losartan on body composition and indices of muscle quality in aged male Fischer 344 \square Brown Norway rats. 2011 , 33, 167-83		34
507	Telmisartan protects against insulin resistance by attenuating inflammatory response in rats. 2011 , 31, 317-323		6
506	Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. 2011 , 71, 964-75		24
505	Development of a new class of benzoylpyrrole-based PPAR δ activators. 2011 , 21, 220-4		3

504	Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α activators. 2011 , 21, 1978-82		10
503	Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR β agonist actions. 2011 , 279, 91-9		18
502	Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis. 2011 , 26, 3131-43		19
501	Regulation of insulin secretion and reactive oxygen species production by free fatty acids in pancreatic islets. 2011 , 3, 213-23		50
500	Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice. 2011 , 152, 1789-99		79
499	Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome. 2011 , 89, 355-64		15
498	Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. <i>Hypertension</i> , 2011 , 58, 635-42	8.5	77
497	Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. 2011 , 12, 1-7		98
496	Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients. 2011 , 97, 1425-32		23
495	Lessons from a mouse model characterizing features of vascular cognitive impairment with white matter changes. 2011 , 2011, 978761		54
494	Advances in neuroprotective strategies: potential therapies for intracerebral hemorrhage. 2011 , 31, 211-22		97
493	Telmisartan attenuates isoproterenol-induced cardiac remodeling in rats via regulation of cardiac adiponectin expression. 2011 , 32, 449-55		9
492	Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR γ Activator. 2011 , 1, 78-90		5
491	Engagement of renin-angiotensin system in prostate cancer. 2011 , 11, 442-50		19
490	Telmisartan inhibits vasoconstriction via PPAR β dependent expression and activation of endothelial nitric oxide synthase. 2011 , 90, 122-9		45
489	High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor γ target genes in patients with the metabolic syndrome. <i>Hypertension</i> , 2011 , 58, 725-32	8.5	28
488	Peroxisome proliferator-activated receptor γ and the endothelium: implications in cardiovascular disease. 2011 , 9, 1279-94		8
487	Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor γ in macrophages. 2011 , 31, 1268-75		37

486	Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. 2011 , 34, 1302-8	23
485	Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. 2011 , 34, 1179-84	18
484	Is insulin resistance a risk factor for the progression of chronic kidney disease?. 2011 , 34, 111-5	10
483	Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPAR α and HO-1. 2011 , 300, F1180-92	135
482	Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes. 2011 , 33, 100-5	7
481	Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. 2011 , 120, 307-19	52
480	Hydrochlorothiazide compared to candesartan treatment increases adipose tissue gene expression and circulating levels of serum amyloid A in hypertensive patients. 2011 , 43, 319-24	2
479	Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2) ²⁷ rat. 2011 , 300, H181-90	17
478	Antihypertensive drugs in patients treated with antiretrovirals. 2012 , 46, 703-9	22
477	How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations?. 2012 , 3, 164	33
476	Peroxisome proliferator-activated receptor- α activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. <i>Hypertension</i> , 2012 , 59, 1079-88	8.5 77
475	Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension. 2012 , 13, 107-12	6
474	Novel concept in the mechanism of injury and protection of gastric mucosa: role of renin-angiotensin system and active metabolites of angiotensin. 2012 , 19, 55-62	22
473	Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPAR α target gene regulation. 2012 , 153, 1103-15	25
472	Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. 2012 , 27, 2255-63	30
471	Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients. 2012 , 34, 523-9	1
470	Valsartan, independently of AT1 receptor or PPAR α suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012 , 302, E286-96	6 28
469	Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT α receptor in the rostral ventrolateral medulla of hypertensive rats. 2012 , 35, 940-6	35

468	Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice. 2012 , 35, 213-20		40
467	And in the end--Telmisartan directly binds to PPAR α 2012 , 35, 704-5		2
466	Effects of telmisartan on the cerebral circulation of hypertensive patients with chronic-stage stroke. 2012 , 35, 1171-5		3
465	Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats. 2012 , 35, 48-54		16
464	Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor- γ /hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. <i>Hypertension</i> , 2012 , 59, 308-16	8.5	41
463	Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension. 2012 , 13, 394-400		6
462	A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications. 2012 , 8, 196-226		2
461	Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. 2012 , 67, 203-11		17
460	Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPAR α activation. 2012 , 59, 570-5		4
459	Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNF α -stimulated human endothelial cells and reduce associated atherogenicity. 2012 , 60, 367-74		6
458	Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats. 2012 , 30, 1992-9		35
457	Different roles of PPAR- δ activity on physiological and pathological alteration after myocardial ischemia. 2012 , 60, 158-64		11
456	Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor- δ activation in human monocytes. 2012 , 30, 87-96		46
455	Telmisartan in the management of diabetic nephropathy: a contemporary view. 2012 , 8, 183-90		19
454	Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension. 2012 , 51, 2091-6		4
453	Candesartan, an angiotensin II AT β receptor blocker and PPAR- δ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. 2012 , 37, 2817-29		81
452	Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. <i>European Journal of Pharmacology</i> , 2012 , 697, 1-12	5.3	66
451	Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. 2012 , 123, 567-90		140

450	Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor β is a potential target for diabetic macrovascular complications. 2012 , 3, 11-23		2
449	Relationship between telmisartan dose and glycaemic control in Japanese patients with type 2 diabetes mellitus and hypertension: a retrospective study. <i>Clinical Drug Investigation</i> , 2012 , 32, 577-82	3-2	1
448	Azilsartan Medoxomil. <i>Clinical Drug Investigation</i> , 2012 , 32, 621-639	3-2	31
447	Inhibition of MCP-1/CCR2 signaling pathway is involved in synergistic inhibitory effects of irbesartan with rosuvastatin on vascular remodeling. 2012 , 6, 375-84		5
446	Noncanonical mechanisms to regulate nuclear receptor signaling. 2012 , 4, 1307-33		4
445	Hemodynamic effects of vasorelaxant compounds in mice lacking one, two or all three angiotensin II receptors. 2012 , 35, 547-51		8
444	Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. 2012 , 17, 34-43		21
443	Angiotensin-(1-7) Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes. 2012 , 33, 174-7		34
442	Telmisartan treatment attenuates arsenic-induced hepatotoxicity in mice. 2012 , 300, 149-57		32
441	Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-)/AT1A(-) double knock out mice. 2012 , 52, 630-7		16
440	Double blockade of angiotensin II (AT(1))-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats. 2012 , 165, 2721-35		25
439	Submaximal PPAR α activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders. 2012 , 166, 1981-92		56
438	The renin-angiotensin system in the pathophysiology of type 2 diabetes. 2012 , 5, 611-24		52
437	Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet. 2012 , 90, 322-7		6
436	Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials. 2012 , 156, 92-6		15
435	Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials. 2012 , 157, 403-7		13
434	An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome. 2012 , 158, 101-2		4
433	Characterization of telmisartan-derived PPAR α agonists: importance of moiety shift from position 6 to 5 on potency, efficacy and cofactor recruitment. 2012 , 7, 1935-42		6

432	Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice. 2012 , 11, 139		50
431	Effect of telmisartan on the expression of adiponectin receptors and nicotinamide adenine dinucleotide phosphate oxidase in the heart and aorta in type 2 diabetic rats. 2012 , 11, 94		26
430	Telmisartan directly ameliorates the neuronal inflammatory response to IL-1 β partly through the JNK/c-Jun and NADPH oxidase pathways. 2012 , 9, 102		68
429	Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue: A possible link to anti-metabolic effects. <i>European Journal of Pharmacology</i> , 2012 , 692, 84-90	5-3	18
428	Therapeutic role of telmisartan against acetaminophen hepatotoxicity in mice. <i>European Journal of Pharmacology</i> , 2012 , 693, 64-71	5-3	12
427	Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques. 2012 , 39, 1232-5		30
426	Angiotensin receptor 1 blocker valsartan normalizes gene expression profiles of 3T3-L1 adipocytes altered by co-culture with LPS-treated RAW264.7 macrophages. 2012 , 6, e263-346		2
425	The combined strategy with PPAR α agonism and AT β receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat. 2012 , 66, 349-56		10
424	Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension. 2012 , 35, 281-9		11
423	Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients. 2012 , 29, 635-44		24
422	Deficiency of angiotensin type 1a receptors in adipocytes reduces differentiation and promotes hypertrophy of adipocytes in lean mice. 2012 , 153, 4677-86		18
421	Renoprotective effects of telmisartan on renal injury in obese Zucker rats. 2012 , 49 Suppl 1, S15-24		13
420	Adipogenic differentiation of adipose tissue-derived human mesenchymal stem cells: effect of gastric bypass surgery. 2012 , 26, 3449-56		11
419	Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats. 2012 , 60, 489-94		44
418	Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates. 2012 , 253-290		6
417	Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR. 2012 , 7, e42469		6
416	Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension. 2012 , 5, 753-8		2
415	The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. 2012 , 302, H1219-30		162

414	Regulation of angiotensin II receptors beyond the classical pathway. 2012 , 123, 193-203		68
413	Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. 2012 , 35, 359-64		23
412	Structural basis for telmisartan-mediated partial activation of PPAR gamma. 2012 , 35, 715-9		41
411	Four novel UCP3 gene variants associated with childhood obesity: effect on fatty acid oxidation and on prevention of triglyceride storage. 2012 , 36, 207-17		21
410	How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?. 2012 , 24, 1583-91		11
409	Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor- α in subtotal nephrectomized rat. <i>European Journal of Pharmacology</i> , 2012 , 685, 91-8	5:3	20
408	Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats. 2012 , 61, 164-74		6
407	Highly practical and cost-efficient synthesis of telmisartan: an antihypertensive drug. 2012 , 68, 2509-2512		17
406	Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. 2012 , 12, 207-14		58
405	Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome. 2012 , 14, 320-8		16
404	Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms. 2012 , 14, 586-95		27
403	Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms. 2013 , 229, 672-84		9
402	Palladium-catalyzed regioselective synthesis of 2(2'-biphenyl)benzimidazoles through C-H activation. 2013 , 17, 641-9		7
401	Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor- α 2013 , 23, 767-72		22
400	Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor α 2013 , 13, 39		18
399	Binding affinity of amlodipine, atorvastatin and telmisartan drugs to purified bacterial melanin pigment: a kinetic study. 2013 , 43, 267-278		6
398	Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice. <i>European Journal of Pharmacology</i> , 2013 , 698, 505-10	5:3	9
397	A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. 2013 , 65, 809-48		189

396	A meta-analysis of randomized head-to-head trials of telmisartan versus other angiotensin II receptor blocker in combination with hydrochlorothiazide for reduction of blood pressure. 2013 , 167, 3062-5	3
395	Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure. 2013 , 7, 11-20	16
394	The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. 2013 , 24, 2003-15	86
393	Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action. 2013 , 37, 156-68	7
392	Enzymes involved in l-lactate metabolism in humans. 2013 , 13, 615-29	60
391	AT1 antagonists: a patent review (2008 - 2012). 2013 , 23, 1483-94	24
390	Effect of amorphization method on telmisartan solubility and the tableting process. 2013 , 83, 114-21	33
389	The Metabolic Syndrome. 2013 ,	6
388	Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. 2013 , 172, 86-95	58
387	The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. 2013 , 48, 602-9	58
386	Direct renin inhibition modulates insulin resistance in caveolin-1-deficient mice. 2013 , 62, 275-81	18
385	Angiotensin-(1-7): beyond the cardio-renal actions. 2013 , 124, 443-56	156
384	Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. 2013 , 99, e21-3	27
383	Adipose tissue renin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance. 2013 , 378, 1-14	49
382	Serum adiponectin levels are significantly associated with favorable metabolic parameters and elevation of atherosclerotic markers. 2013 , 167, 3065-6	2
381	Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. 2013 , 167, 1443-9	15
380	Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers. 2013 , 75, 415-22	3
379	Discovery of a novel selective PPAR α ligand with partial agonist binding properties by integrated in silico/in vitro work flow. 2013 , 53, 923-37	25

378	Systematic exploration of dual-acting modulators from a combined medicinal chemistry and biology perspective. 2013 , 56, 1197-210	13
377	Treatment of Hypertension in the Metabolic Syndrome. 2013 , 185-190	
376	Regulation of selective PPAR δ modulators in the differentiation of osteoclasts. 2013 , 114, 1969-77	13
375	Does the PPAR δ -activating property of telmisartan provide a benefit in clinical practice?. 2013 , 36, 183	6
374	Blood pressure-independent effects of telmisartan on regression of left ventricular mass: a meta-analysis and meta-regression of randomized controlled trials. 2013 , 165, 564-7	6
373	Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension. 2013 , 36, 608-13	51
372	Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. 2013 , 36, 368-73	27
371	Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. 2013 , 185, 1035-41	15
370	Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPAR δ agonists. 2013 , 170, 1137-51	27
369	Inhibitors of difficult protein-protein interactions identified by high-throughput screening of multiprotein complexes. 2013 , 8, 1988-1997	38
368	Captopril and telmisartan treatments attenuate cadmium-induced testicular toxicity in rats. 2013 , 27, 152-60	19
367	Effect of chronic treatment with angiotensin receptor ligands on water-salt balance in Wistar and spontaneously hypertensive rats. 2013 , 55, 63-9	4
366	Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor- δ activation in hypertensive 5/6 nephrectomized rats. 2013 , 92, 265-75	9
365	Combination of telmisartan with cisplatin controls oral cancer cachexia in rats. 2013 , 2013, 642848	10
364	Sympathoexcitation associated with Renin-Angiotensin system in metabolic syndrome. 2013 , 2013, 406897	16
363	Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). 2013 , 2013, 587140	52
362	Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptor δ -hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension. 2013 , 2, e000103	28
361	Effect of angiotensin II receptor blocker on experimental periodontitis in a mouse model of Marfan syndrome. 2013 , 81, 182-8	19

360	A clinical link between peroxisome proliferator-activated receptor α and the renin-angiotensin system. 2013 , 33, 676-8	6
359	Tissue-specific peroxisome proliferator activated receptor gamma expression and metabolic effects of telmisartan. 2013 , 26, 829-35	8
358	The Effects of Telmisartan and Losartan on Insulin Sensitivity. 2013 , 17, 92-97	
357	The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO). 2013 , 10, 93-6	26
356	Telmisartan modulates mitochondrial function in vascular smooth muscle cells. 2013 , 36, 433-9	11
355	Choosing the right angiotensin-receptor blocker for patients with diabetes: still controversial. 2013 , 185, 1023-4	1
354	Valsartan restores inflammatory response by macrophages in adipose and hepatic tissues of LPS-infused mice. 2013 , 2, 28-32	8
353	Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor- α activation. 2013 , 62, 762-74	37
352	Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. 2013 , 60, 563-70	12
351	Improvement of metabolic syndrome by irbesartan via the PPAR γ /HGF pathway in apolipoprotein E knockout mice. 2013 , 1, 65-70	7
350	Validated specific densitometric method for simultaneous estimation of telmisartan and atorvastatin in presence of degradation products formed under ICH-recommended stress conditions. 2013 , 26, 445-451	1
349	The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor- α activating capacity on plasma 8-isoprostane prostaglandin F _{2a} levels. 2013 , 9, 172-6	10
348	Vascular Pharmacology. 2013 , 75-93	1
347	Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study. 2014 , 8, 219-26	2
346	Endothelial progenitor cells in cardiovascular diseases. 2014 , 6, 355-66	106
345	KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes. 2014 , 9, e87848	23
344	Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. 2014 , 9, e93050	35
343	The therapeutic role of Renin-Angiotensin System blockers in obesity-related renal disorders. 2014 , 9, 2-9	15

342	Non-alcoholic fatty liver disease: what the clinician needs to know. 2014 , 20, 12956-80	117
341	The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. 2014 , 355, 46-53	50
340	Effect of Semecarpus anacardium on diabetes-induced alterations in the activities of marker enzymes and antioxidant enzymes in type 2 diabetes induced cardiac vascular damage model in rats. 2014 , 11, 347-60	1
339	Expressional profile of cardiac uncoupling protein-2 following myocardial ischemia reperfusion in losartan- and ramiprilat-treated rats. 2014 , 15, 209-17	14
338	References. 2014 , 37, 362-387	37
337	Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity. 2014 , 37, 621-8	15
336	Telmisartan activates endogenous peroxisome proliferator-activated receptor- α and may have anti-fibrotic effects in human mesangial cells. 2014 , 37, 422-31	26
335	Chapter 5. Treatment with antihypertensive drugs. 2014 , 37, 291-300	2
334	eMatchSite: sequence order-independent structure alignments of ligand binding pockets in protein models. 2014 , 10, e1003829	23
333	Telmisartan inhibits the proinflammatory effects of homocysteine on human endothelial cells through activation of the peroxisome proliferator-activated receptor- γ pathway. 2014 , 34, 828-34	14
332	Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat. 2014 , 23, 2580-2590	25
331	Long-term amelioration of telmisartan on metabolic syndrome-related molecules in stroke-resistant spontaneously hypertensive rat after transient middle cerebral artery occlusion. 2014 , 23, 2646-2653	4
330	The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. 2014 , 121, 217-66	55
329	Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells. 2014 , 39, 66-72	10
328	Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats. 2014 , 15, 410-8	9
327	Protective effect of telmisartan against progressive oxidative brain damage and synuclein phosphorylation in stroke-resistant spontaneously hypertensive rats. 2014 , 23, 1545-53	9
326	Comparision of secretagogue effects of rosiglitazone and telmisartan on ANP secretion in rats. 2014 , 56, 52-8	4
325	Telmisartan complex augments solubility, dissolution and drug delivery in prostate cancer cells. 2014 , 101, 614-22	18

324	Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zucker rats. 2014 , 6, 10	4
323	Olmesartan and telmisartan comparably preserve pancreatic beta-cell mass with reduction of oxidative stress in db/db mice. 2014 , 5, 62-68	3
322	Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents. 2014 , 53, 4056-75	32
321	Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPAR α activation. 2014 , 79, 249-61	65
320	Synthesis and characterisation of starch tartrate and its application as novel disintegrant in telmisartan tablets. 2014 , 66, 409-417	1
319	Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPAR α agonists. 2014 , 24, 1098-103	17
318	Azilsartan improves glycemic status and reduces kidney damage in Zucker diabetic fatty rats. 2014 , 27, 1087-95	12
317	Enhanced pan-peroxisome proliferator-activated receptor gene and protein expression in adipose tissue of diet-induced obese mice treated with telmisartan. 2014 , 99, 1663-78	19
316	The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. 2014 , 62, 189-96	68
315	Telmisartan, a possible PPAR α agonist, reduces TNF α -stimulated VEGF-C production by inhibiting the p38MAPK/HSP27 pathway in human proximal renal tubular cells. 2014 , 454, 320-7	10
314	To compare the effect of Telmisartan with Metoprolol on arterial stiffness in hypertension: prospective randomized parallel group trial. 2014 , 66, 415-21	6
313	Chronic blockade of angiotensin AT α receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. 2014 , 171, 746-60	33
312	A one-pot tandem synthesis of various 1,2-disubstituted benzimidazoles. 2014 , 55, 4697-4700	11
311	Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPAR α and the Akt/GSK-3 β pathway. 2014 , 35, 727-37	27
310	Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats. 2014 , 6, 57	15
309	A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation. 2014 , 37, 845-51	8
308	Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor α among clinically used angiotensin II receptor blockers: drug-target interaction analyses. 2014 , 349, 10-20	14
307	Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. 2014 , 13, 91	16

306	Peroxisome proliferator-activated receptor gamma concentrations in newly diagnosed hypertension patients and the metabolic effects of olmesartan. 2014 , 45, 138-42	4
305	Angiotensin II receptor blockers differentially affect CYP11B2 expression in human adrenal H295R cells. 2014 , 383, 60-8	6
304	Telmisartan attenuates cognitive impairment caused by chronic stress in rats. 2014 , 66, 436-41	34
303	A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. 2014 , 8, 578-92	12
302	The ACE2/Ang-(1-7)/Mas axis can inhibit hepatic insulin resistance. 2014 , 393, 30-8	54
301	Telmisartan treatment ameliorates memory deficits in streptozotocin-induced diabetic mice via attenuating cerebral amyloidosis. 2014 , 124, 418-26	13
300	Antihypertensive drugs and glucose metabolism. 2014 , 6, 517-30	51
299	Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients. 2014 , 78, 240-7	20
298	Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. 2014 , 32, 1334-41	11
297	Herzregeneration: Chancen und Aufgaben für die Wirkstoff-Forschung mit neuartigen chemischen und therapeutischen Methoden oder Agentien. 2014 , 126, 4138-4159	2
296	Drug Repurposing Patent Applications October-December 2014. 2015 , 1, 8-14	
295	Telmisartan attenuates peritoneal fibrosis via peroxisome proliferator-activated receptor- α activation in rats. 2015 , 42, 671-9	5
294	The Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Postangioplasty Restenosis. 2015 , 22, e107-14	1
293	Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvation. 2015 , 8, 103-13	14
292	Cardiometabolic properties of telmisartan: new perspectives for use. 2015 , 11, 650-654	
291	Impact of peroxisome proliferator-activated receptor γ on angiotensin II type 1 receptor-mediated insulin sensitivity, vascular inflammation and atherogenesis in hypercholesterolemic mice. 2015 , 11, 877-85	3
290	Metabolic Effects of AT2R Stimulation in Adipose Tissue. 2015 , 119-123	
289	Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure. 2015 , 73-118	

288	Angiotensin II receptor blockade and skeletal muscle metabolism in overweight and obese adults with elevated blood pressure. 2015 , 9, 45-50	2
287	Hypertension and Dyslipidemia in Patients with Pre-Diabetes: Dietary and Other Therapies. 2015 , 157-179	
286	Therapeutic interventions using a combination of Telmisartan and omega 3-fatty acids in sodium arsenite-induced vascular endothelial dysfunction in rats: modulation through ATP-sensitive K ⁺ channels and eNOS. 2015 , 12, 143-51	3
285	Drug Repurposing Patent Applications October-December 2014. 2015 , 13, 325-331	1
284	Angiotensin II AT1 receptor blockade by telmisartan reduces impairment of spatial maze performance induced by both acute and chronic stress. 2015 , 16, 495-505	18
283	Long-term use of angiotensin II receptor antagonists and calcium-channel antagonists in Algerian hypertensive patients: effects on metabolic and oxidative parameters. 2015 , 79, 147-53	5
282	Telmisartan attenuates the inflamed mesenteric adipose tissue in spontaneous colitis by mechanisms involving regulation of neurotensin/microRNA-155 pathway. 2015 , 93, 461-9	14
281	Telmisartan enhances mitochondrial activity and alters cellular functions in human coronary artery endothelial cells via AMP-activated protein kinase pathway. 2015 , 239, 375-85	15
280	Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. 2015 , 38, 252-9	35
279	A convergent approach to the total synthesis of telmisartan via a Suzuki cross-coupling reaction between two functionalized benzimidazoles. 2015 , 80, 1915-9	18
278	Peroxisome Proliferator-Activated Receptor α (PPAR α) and Ligand Choreography: Newcomers Take the Stage. 2015 , 58, 5381-94	61
277	Genotoxic Impurities in Pharmaceutical Manufacturing: Sources, Regulations, and Mitigation. 2015 , 115, 8182-229	97
276	Investigation of the effect of telmisartan on experimentally induced peripheral nerve injury in rats. 2015 , 125, 464-73	8
275	Neurorestoration after traumatic brain injury through angiotensin II receptor blockage. 2015 , 138, 3299-315	82
274	Effects of Exercise on Hypertension. 2015 ,	2
273	Identification of a novel selective agonist of PPAR α with no promotion of adipogenesis and less inhibition of osteoblastogenesis. 2015 , 5, 9530	50
272	Telmisartan-induced PPAR α activity attenuates lipid accumulation in VSMCs via induction of autophagy. 2015 , 42, 179-86	28
271	Development and validation of a liquid chromatography-mass spectrometry method for simultaneous determination of metoprolol and telmisartan in rat plasma and its application to pharmacokinetic study. 2015 , 45, 329-340	6

270	Combination therapy with telmisartan and oxacalcitriol suppresses the progression of murine adriamycin nephropathy. 2015 , 129, 143-54		7
269	Spinal NF- κ B and chemokine ligand 5 expression during spinal glial cell activation in a neuropathic pain model. 2015 , 10, e0115120		26
268	Role and therapeutic potential of G-protein coupled receptors in breast cancer progression and metastases. <i>European Journal of Pharmacology</i> , 2015 , 763, 178-83	5-3	22
267	Investigations in foot shock stress of variable intensity in mice: Adaptation and role of angiotensin II. <i>European Journal of Pharmacology</i> , 2015 , 761, 86-94	5-3	6
266	Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications. 2015 , 17, 558		31
265	Comparative effects of Aliskiren and Telmisartan in high fructose diet-induced metabolic syndrome in rats. <i>European Journal of Pharmacology</i> , 2015 , 760, 145-53	5-3	24
264	Telmisartan attenuated LPS-induced neuroinflammation in human IMR-32 neuronal cell line via SARM in AT1R independent mechanism. 2015 , 130, 88-96		13
263	Endothelial Cell Function and Hypertension: Interactions Among Inflammation, Immune Function, and Exercise. 2015 , 301-323		1
262	Hepatic expression of serum amyloid A1 is induced by traumatic brain injury and modulated by telmisartan. 2015 , 185, 2641-52		26
261	Cinnamaldehyde Contributes to Insulin Sensitivity by Activating PPAR α /PPAR δ and RXR. 2015 , 43, 879-92		18
260	Telmisartan mediates anti-inflammatory and not cognitive function through PPAR δ -agonism via SARM and MyD88 signaling. 2015 , 137, 60-8		22
259	Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO. 2015 , 6, 107-15		16
258	ACEi and ARBS in Hypertension and Heart Failure. 2015 ,		1
257	Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats. 2015 , 172, 857-68		26
256	Neuroprotective effects of angiotensin receptor blockers. 2015 , 28, 289-99		122
255	Combining rosuvastatin with angiotensin-receptor blockers of different PPAR δ -activating capacity: effects on high-density lipoprotein subfractions and associated enzymes. 2015 , 66, 36-42		5
254	Efficacy and safety of combination therapy of high-dose losartan and hydrochlorothiazide in patients with hypertension. 2015 , 16, 1078-84		1
253	Prevention of metabolic disorders with telmisartan and indapamide in a Chinese population with high-normal blood pressure. 2015 , 38, 123-31		5

252	Detection, isolation and characterization of principle synthetic route indicative impurity in telmisartan. 2016 , 9, S1516-S1522		5
251	Combination of Telmisartan and Linagliptin Preserves Pancreatic Islet Cell Function and Morphology in db/db Mice. 2016 , 45, 584-92		8
250	Effects of captopril, telmisartan and bardoxolone methyl (CDDO-Me) in ischemia-reperfusion-induced acute kidney injury in rats: an experimental comparative study. 2016 , 43, 230-41		18
249	Comparison of telmisartan/amlodipine and telmisartan/hydrochlorothiazide in the treatment of Japanese patients with uncontrolled hypertension: the TAT-Kobe study. 2016 , 21, 171-7		1
248	Angiotensin II type 1 receptor blockade by telmisartan prevents stress-induced impairment of memory via HPA axis deactivation and up-regulation of brain-derived neurotrophic factor gene expression. 2016 , 148, 108-18		20
247	Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor- α activation in an obese rat model. 2016 , 12, 272-278		3
246	Drug Repurposing Patent Applications July-September 2016. 2016 , 14, 577-582		1
245	High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with <i>Lactobacillus rhamnosus</i> GG (LGG) or telmisartan in ApoE mice. 2016 , 16, 264		70
244	Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells. 2016 , 6, 442-60		25
243	Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats. 2016 , 94, 907-17		12
242	Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 81, 136-144	7.5	11
241	Recent advances in the synthesis of benzimidazol(on)es via rearrangements of quinoxalin(on)es. 2016 , 6, 42132-42172		51
240	Rearrangements of Quinoxalin(on)es for the Synthesis of Benzimidazol(on)es. 2016 , 343-422		0
239	Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. 2016 , 64, 1102-8		6
238	Recent Progress in Metal Catalyzed Direct Carboxylation of Aryl Halides and Pseudo Halides Employing CO ₂ : Opportunities for 11C Radiochemistry. 2016 , 8, 3692-3700		21
237	New telmisartan-derived PPAR α agonists: Impact of the 3D-binding mode on the pharmacological profile. 2016 , 124, 138-152		17
236	Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. 2016 , 72, 1471-1478		11
235	Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat. 2016 , 81, 155-161		5

234	Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet. 2016 , 131, 190-7		10
233	Renoprotective effect of a combination of garlic and telmisartan against ischemia/reperfusion-induced kidney injury in obese rats. 2016 , 50, 966-86		7
232	Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor α (PPAR α) from bedside to bench. 2016 , 15, 113		22
231	Micro RNA-320 as a novel potential biomarker in renal ischemia reperfusion. 2016 , 38, 1468-1475		10
230	Functionalized Benzimidazole Scaffolds: Privileged Heterocycle for Drug Design in Therapeutic Medicine. 2016 , 349, 475-506		37
229	Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia. 2016 , 154, 15-23		14
228	Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region. 2016 , 15, 24		7
227	Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release From Perirenal Adipose Tissue. <i>Hypertension</i> , 2016 , 68, 478-90	8.5	34
226	Primary hypertension is a disease of premature vascular aging associated with neuro-immuno-metabolic abnormalities. 2016 , 31, 185-94		20
225	Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders. 2016 , 76, 1-12		32
224	Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease. 2016 , 36, 259-79		54
223	Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. 2016 , 32, 1303-9		9
222	Inhibition of endoplasmic reticulum stress-activated IRE1 α /TRAF2-caspase-12 apoptotic pathway is involved in the neuroprotective effects of telmisartan in the rotenone rat model of Parkinson's disease. <i>European Journal of Pharmacology</i> , 2016 , 776, 106-15	5.3	53
221	Increase of human prostate cancer cell (DU145) apoptosis by telmisartan through PPAR-delta pathway. <i>European Journal of Pharmacology</i> , 2016 , 775, 35-42	5.3	16
220	Metabolic syndrome update. 2016 , 26, 364-73		378
219	Identification of a novel selective PPAR δ ligand with a unique binding mode and improved therapeutic profile in vitro. 2017 , 7, 41487		12
218	Telmisartan: clinical evidence across the cardiovascular and renal disease continuum. 2017 , 33, 77-87		2
217	Copper-Mediated Late-Stage Functionalization of Heterocycle-Containing Molecules. 2017 , 129, 5401-5405		11

216	Copper-Mediated Late-Stage Functionalization of Heterocycle-Containing Molecules. 2017 , 56, 5317-5321	68
215	A review of chemical therapies for treating diabetic hypertension. 2017 , 18, 909-923	5
214	Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy. 2017 , 35, 1442-1456	9
213	Protein Function Prediction. 2017 ,	9
212	Local Alignment of Ligand Binding Sites in Proteins for Polypharmacology and Drug Repositioning. 2017 , 1611, 109-122	9
211	A Benzoquinone Imine Assisted Ring-Opening/Ring-Closing Strategy of the RCOCHN1N2 System: Dinitrogen Extrusion Reaction to Benzimidazoles. 2017 , 2017, 2751-2756	6
210	Telmisartan and hydrochlorothiazide antihypertensive treatment in high sodium intake population: a randomized double-blind trial. 2017 , 35, 2077-2085	1
209	PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR- α and PPAR- γ 2017 , 13, 279-296	97
208	Protective effects of telmisartan and tempol on lipopolysaccharide-induced cognitive impairment, neuroinflammation, and amyloidogenesis: possible role of brain-derived neurotrophic factor. 2017 , 95, 850-860	20
207	Shear Stress in Autophagy and Its Possible Mechanisms in the Process of Atherosclerosis. 2017 , 36, 335-346	11
206	Losartan Improves Palmitate-Induced Insulin Resistance in 3T3-L1 Adipocytes Through Upregulation of Src Phosphorylation. 2017 , 125, 136-140	4
205	Importance of 5/6-aryl substitution on the pharmacological profile of 4'-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid derived PPAR α agonists. 2017 , 126, 590-603	6
204	Method development and validation: quantitation of telmisartan bulk drug and its tablet formulation by H NMR spectroscopy. 2017 , 55, 634-638	4
203	Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. 2017 , 51, 1674-1684	27
202	Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. 2017 , 14, 2689-2694	13
201	Dual-Acting Compounds Acting as Receptor Ligands and Enzyme Inhibitors. 2017 , 137-165	5
200	Telmisartan ameliorates adipoR1 and adipoR2 expression via PPAR- α activation in the coronary artery and VSMCs. <i>Biomedicine and Pharmacotherapy</i> , 2017 , 95, 129-136	7.5 9
199	A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. 2017 , 8, 573	295

198	PPAR α agonists: Potential treatments for exudative age-related macular degeneration. 2017 , 188, 123-130	14
197	Potential of telmisartan in the treatment of benign prostatic hyperplasia. 2017 , 31, 643-651	1
196	Multiple Ligands Targeting the Angiotensin System for Hypertension. 2017 , 369-395	
195	Multiple Peroxisome Proliferator-Activated Receptor-Based Ligands. 2017 , 397-432	
194	Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders. 2017 , 50, 233-247	7
193	Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor- β by core hopping of telmisartan. 2017 , 35, 2665-2680	10
192	. 2017 ,	2
191	Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review. 2017 , 5, 101	16
190	Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers. 2017 , 11, 3543-3550	5
189	Effects of Azilsartan, Aliskiren or their Combination on High Fat Diet-induced Non-alcoholic Liver Disease Model in Rats. 2017 , 71, 251-255	3
188	Valsartan. 2017 ,	
187	The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPK/mTOR pathway in vitro and in vivo. 2017 , 8, 8536-8549	26
186	Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPAR γ . 2017 , 8, 25612-25627	4
185	Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELMisartan-rosuvaSTatin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study. 2018 , 40, 676-691.e1	10
184	The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. 2018 , 41, 394-405	25
183	Chronic AT1 blockade improves glucose homeostasis in obese OLETF rats. 2018 , 237, 271-284	13
182	Cardiovascular and renal protective role of angiotensin blockade in hypertension with advanced CKD: a subgroup analysis of ATTEMPT-CVD randomized trial. 2018 , 8, 3150	4
181	Development and biological evaluation of vesicles containing bile salt of telmisartan for the treatment of diabetic nephropathy. 2018 , 46, 532-539	9

180	Current Applications of SuzukiMiyaura Coupling Reaction in The Total Synthesis of Natural Products: An update. 2018 , 32, e4210	91
179	Enhanced SIA-chemiluminescence probes for angiotensin II receptor antagonist detection using silver and gold nanoparticles: applications in pharmaceutical formulations. 2018 , 42, 3383-3393	3
178	Transition metal-free and base-mediated transformation arylation of unactivated benzene with aryl halides in presence of N,N'-bis(salicylidene)ethylenediamine as organocatalyst. 2018 , 107, 87-91	6
177	Telmisartan Improves Insulin Resistance: A Meta-Analysis. 2018 , 25, e642-e651	15
176	Effect of Telmisartan on Preventing Learning and Memory Deficits Via Peroxisome Proliferator-Activated Receptor- α In Vascular Dementia Spontaneously Hypertensive Rats. 2018 , 27, 277-285	16
175	FORMULATION AND EVALUATION OF TELMISARTAN SOLID DISPERSIONS USING ENTADA SCANDENS SEED STARCH AND POLOXAMER-188 AS SUPERDISINTEGRANTS. 2018 , 11, 474	1
174	Methyl Red as Organocatalyst for Arylation of Unactivated Benzene Derivatives with Aryl Halides. 2018 , 3, 11517-11521	2
173	Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor- α and angiotensin II type 1 receptor. 2018 , 158, 334-352	2
172	Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis. 2018 , 10, 9-17	8
171	Maintenance of Kidney Metabolic Homeostasis by PPAR Gamma. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6,3 32
170	Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPAR α derived from the AT1R antagonist, Fimasartan. 2018 , 28, 3155-3160	5
169	Effects of telmisartan on TNF α -induced PPAR β phosphorylation and insulin resistance in adipocytes. 2018 , 503, 3044-3049	12
168	Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. 2019 , 62, 420-444	188
167	Telmisartan Protects a Microglia Cell Line from LPS Injury Beyond AT1 Receptor Blockade or PPAR α Activation. 2019 , 56, 3193-3210	10
166	Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study. 2019 , 41, 1508-1521	4
165	Telmisartan, an angiotensin II receptor blocker, attenuates Prevotella intermedia lipopolysaccharide-induced production of nitric oxide and interleukin-1 β in murine macrophages. 2019 , 75, 105750	6
164	Discovery of BR102375, a new class of non-TZD PPAR γ full agonist for the treatment of type 2 diabetes. 2019 , 29, 2275-2282	1
163	Rosmarinic acid monotherapy is better than the combination of rosmarinic acid and telmisartan in preventing podocyte detachment and inhibiting the progression of diabetic nephropathy in rats. 2019 , 13, 179-190	2

162	Cigarette Smoke Extract Modulates Functions of Peroxisome Proliferator-Activated Receptors. <i>Biological and Pharmaceutical Bulletin</i> , 2019 , 42, 1628-1636	2.3	
161	Reversing activity of cancer associated fibroblast for staged glycolipid micelles against internal breast tumor cells. 2019 , 9, 6764-6779		17
160	In vivo identification of small molecules mediating Gpr126/Adgrg6 signaling during Schwann cell development. 2019 , 1456, 44-63		9
159	Serum PGE2, 15d-PGJ, PPAR α and CRP levels in patients with schizophrenia. 2019 , 46, 24-28		6
158	Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. 2019 , 41, 233-248.e9		4
157	Exploitation of localized surface plasmon resonance of silver/gold nanoparticles for the fluorescence quantification of angiotensin II receptor antagonists in their tablets and bio-samples. 2019 , 43, 492-503		4
156	Even Short-Term Telmisartan Treatment Ameliorated Insulin Resistance But Had No Influence on Serum Adiponectin and Tumor Necrosis Factor-Alpha Levels in Hypertensive Patients with Metabolic Syndrome. 2019 , 17, 167-172		2
155	Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model. <i>World Journal of Hepatology</i> , 2019 , 11, 359-369	3-4	14
154	Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. 2019 , 62, 8881-8914		92
153	Investigation of Crystallization and Salt Formation of Poorly Water-Soluble Telmisartan for Enhanced Solubility. <i>Pharmaceutics</i> , 2019 , 11,	6.4	7
152	Telmisartan protects against high glucose/high lipid-induced apoptosis and insulin secretion by reducing the oxidative and ER stress. 2019 , 37, 161-168		20
151	Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan. 2019 , 9, 4003		9
150	Multitarget PPAR α agonists as innovative modulators of the metabolic syndrome. 2019 , 173, 261-273		18
149	Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial. 2019 , 14, e0214727		11
148	Telmisartan induces browning of fully differentiated white adipocytes via M2 macrophage polarization. 2019 , 9, 1236		12
147	Multimodal Intervention to Improve Functional Status in Hypertensive Older Adults: A Pilot Randomized Controlled Trial. 2019 , 8,		5
146	Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. 2019 , 236, 1949-1957		1
145	Antihypertensive and Target-Organ Protective Properties of Telmisartan and Hydrochlorothiazide Single-Pill Combination. 2019 , 15, 558-567		2


144	Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases. 2019 , 9,	34
143	Effects of Telmisartan and Candesartan on the Metabolism of Lipids and Glucose in Kidney Transplant Patients: A Prospective, Randomized Crossover Study. 2019 , 5, e423	
142	Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. 2019 , 79, 75-84	13
141	Recent Progress of Basic Studies of Natural Products and Their Dental Application. 2018 , 6,	11
140	Modulation of inducible nitric oxide synthase pathway by eugenol and telmisartan in carbon tetrachloride-induced liver injury in rats. 2019 , 216, 207-214	21
139	Underlying Mechanisms of Renal Lipotoxicity in Obesity. 2019 , 143, 28-32	27
138	Obesity-Hypertension Physiopathology and Treatment: A Forty-Year Retrospect. 2019 , 197-229	
137	A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. 2019 , 41, 75-79	8
136	Telmisartan Influences the Antiproliferative Activity of Linoleic Acid in Human Colon Cancer Cells. 2020 , 72, 98-109	5
135	Telmisartan ameliorates A β oligomer-induced inflammation via PPAR γ /PTEN pathway in BV2 microglial cells. 2020 , 171, 113674	14
134	Pioglitazone and PPAR γ -modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study. 2020 , 19, 2	8
133	Pancreatic stellate cells in the islets as a novel target to preserve the pancreatic β cell mass and function. 2020 , 11, 268-280	10
132	Quantitative Structure-Activity Relationship Machine Learning Models and their Applications for Identifying Viral 3CLpro- and RdRp-Targeting Compounds as Potential Therapeutics for COVID-19 and Related Viral Infections. 2020 , 5, 27344-27358	12
131	Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques. 2020 , 1-19	17
130	Effect of telmisartan and vitamin E on liver histopathology with non-alcoholic steatohepatitis: A randomized, open-label, noninferiority trial. 2020 , 4, 663-669	2
129	Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan. 2020 , 21, 1179-1190	2
128	Telmisartan, an Antagonist of Angiotensin II Receptors, Accentuates Voltage-Gated Na Currents and Hippocampal Neuronal Excitability. 2020 , 14, 902	4
127	Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. 2020 , 22, 1835-1845	3

126	PPARs and Myocardial Infarction. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
125	Chronically infused angiotensin II induces depressive-like behavior via microglia activation. 2020 , 10, 22082		5
124	Experimental Exposure Assessment of Ionizable Organic Chemicals in Cell-Based Bioassays. 2020 , 33, 1845-1854		3
123	Telmisartan Protects Auditory Hair Cells from Gentamicin-Induced Toxicity in vitro. 2020 , 25, 297-308		0
122	Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts. 2020 , 401, 115112		7
121	Beneficial Effects of Isoflavones in the Kidney of Obese Rats Are Mediated by PPAR-Gamma Expression. 2020 , 12,		2
120	Repurposing old drugs to fight multidrug resistant cancers. 2020 , 52, 100713		29
119	Current Trends in the Treatment of Hypertension: Focus on Improving Prognosis. The Capabilities of an Amlodipine/Telmisartan Single-Pill Combination. 2020 , 15, 906-917		
118	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPAR α activation and on growth of imatinib-resistant chronic myelogenous leukemia cells. 2020 , 195, 112258		2
117	The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI). <i>Pharmacology & Therapeutics</i> , 2021 , 218, 107684	13.9	7
116	Telmisartan detection by UV spectrophotometry in mice drinking water. 2021 , 2, 408-415		
115	Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. 2021 , 100, 22-31		4
114	The emergence of the C-H functionalization strategy in medicinal chemistry and drug discovery. 2021 , 57, 10842-10866		7
113	Telmisartan Inhibits the NLRP3 Inflammasome by Activating the PI3K Pathway in Neural Stem Cells Injured by Oxygen-Glucose Deprivation. 2021 , 58, 1806-1818		2
112	A Novel Mitochondrial Complex of Aldosterone Synthase, Steroidogenic Acute Regulatory Protein, and Tom22 Synthesizes Aldosterone in the Rat Heart. 2021 , 377, 108-120		5
111	ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders. 2021 , 135, 535-554		8
110	Angiotensin II receptor 1 controls profibrotic Wnt/ β -catenin signalling in experimental autoimmune myocarditis. 2021 ,		4
109	Transcriptomic Analysis of Mouse Brain After Traumatic Brain Injury Reveals That the Angiotensin Receptor Blocker Candesartan Acts Through Novel Pathways. 2021 , 15, 636259		3

108	Quantitative -to- Extrapolation: Nominal versus Freely Dissolved Concentration. 2021 , 34, 1175-1182	0
107	Multi-Target Approaches in Metabolic Syndrome. 2020 , 11, 554961	11
106	Highly Efficient and Practical Synthesis of the Key Intermediate of Telmisartan. 2021 , 25, 1022-1027	2
105	An insight into the role of telmisartan as PPAR- β dual activator in the management of nonalcoholic fatty liver disease. 2021 ,	3
104	Electrospun orally disintegrating film formulation of telmisartan. 2021 , 26, 661-672	3
103	Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records. 2021 , 10, 255-269	1
102	Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis. 2021 , 2021, 6628469	0
101	Inhibition of the Renin-Angiotensin System Reduces Gene Expression of Inflammatory Mediators in Adipose Tissue Independent of Energy Balance. 2021 , 12, 682726	1
100	Renin-angiotensin system in intestinal inflammation-Angiotensin inhibitors to treat inflammatory bowel diseases?. 2021 , 129, 161-172	0
99	Telmisartan Attenuates the Growth of Epithelium-like Cells and Glomerular Injury in Spontaneously Hypertensive Rats. 2021 , 41, 498-504	0
98	Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. 2021 , 18, e1003707	1
97	Effect of Telmisartan on Arsenic-Induced (Sub-chronic) Perturbations in Redox Homeostasis, Pro-inflammatory Cascade and Aortic Dysfunction in Wistar Rats. 2021 , 1	0
96	Effects of Statins on Renin-Angiotensin System. 2021 , 8,	1
95	Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist. 2021 , 64, 10581-10605	9
94	Acetic Acid Mediated Electrochemical Synthesis of Benzazole and its Application in the Synthesis of Pharmaceutically Active Compounds. 2021 , 6, 8080-8084	
93	Peroxisome proliferator-activated receptor agonist (pioglitazone) with exogenous adiponectin ameliorates arterial stiffness and oxidative stress in diabetic Wistar Kyoto rats. <i>European Journal of Pharmacology</i> , 2021 , 907, 174218	5.3 2
92	Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 2
91	Telmisartan alleviates alcohol-induced liver injury by activation of PPAR- β /Nrf-2 crosstalk in mice. 2021 , 99, 107963	5

90	Potential therapeutic agents for ischemic white matter damage. 2021 , 149, 105116			1
89	PPAR Modulation Through Posttranslational Modification Control. 2021 , 537-611			1
88	Toxicogenomic identification of repositioned therapy for a monogenic disease.			2
87	CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPAR β signaling. 2013 , 123, 299-314			38
86	Comparative pharmacology of angiotensin II (AT1) receptor antagonists. 2006 , 13-30			1
85	Partial agonist, telmisartan, maintains PPAR β Serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass. 2014 , 9, e96323			34
84	Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells. 2014 , 9, e96948			11
83	Efficacy and Safety of Combination Therapy Consisting of Angiotensin II Type 1 Receptor Blocker, Calcium Channel Blocker and Hydrochlorothiazide in Patients With Hypertension. 2017 , 9, 98-103			1
82	Adipokines and cardiovascular diseases: clinical and therapeutic value. 2020 , 2020, 47-53			1
81	[Hypertension in diabetes mellitus]. 2009 , 150, 1813-23			2
80	Telmisartan in the hypertension treatment: from pharmacological characteristics to clinical benefits. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020 , 19, 106-117	0.9		1
79	Telmisartan inhibits hyperalgesia and inflammatory progression in a diabetic neuropathic pain model of Wistar rats. 2015 , 20, 115-23			14
78	Azilsartan medoxomil: a review of its use in hypertension. <i>Clinical Drug Investigation</i> , 2012 , 32, 621-39	3.2		13
77	PPAR γ Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism. 2019 , 20, 1281-1294			12
76	The mechanisms of development cardiovascular disease and type 2 diabetes: the role of insulin resistance, hyperinsulinemia and hypo adiponectinemia. Treatment and management. <i>Systemic Hypertension</i> , 2014 , 11, 48-53	1.6		1
75	The protective effect of telmisartan in Type 2 diabetes rat kidneys is related to the downregulation of thioredoxin-interacting protein. 2013 , 36, 453-9			8
74	Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series. 2007 , 48, 864-70			12
73	Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/eNOS pathway and NO release in spontaneously hypertensive rats. <i>Physiological Research</i> , 2013 , 62, 351-9	2.1		19

72	Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. 2006 , 12, 4369-76		42
71	Telmisartan Inhibits TNF α -Induced Leukocyte Adhesion by Blocking ICAM-1 Expression in Astroglial Cells but Not in Endothelial Cells. <i>Biomolecules and Therapeutics</i> , 2020 , 28, 423-430	4.2	3
70	Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. <i>Saudi Journal of Gastroenterology</i> , 2016 , 22, 69-76	3	35
69	Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open-label Study. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2017 , 8, 106-111	0.2	9
68	PPAR and Local Renin-Angiotensin Systems in Cardiovascular and Metabolic Diseases Associated with Obesity: A Unifying Hypothesis. <i>Open Journal of Endocrine and Metabolic Diseases</i> , 2013 , 03, 1-10	0.1	1
67	Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus. <i>World Journal of Diabetes</i> , 2014 , 5, 678-88	4.7	15
66	Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade. <i>World Journal of Hepatology</i> , 2017 , 9, 74-79	3.4	9
65	Effect of the angiotensin II receptor antagonist telmisartan on lipoprotein lipase mass in preheparin serum. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008 , 15, 138-45	4	9
64	Antioxidant Potential of Adiponectin and Full PPAR- Agonist in Correcting Streptozotocin-Induced Vascular Abnormality in Spontaneously Hypertensive Rats. <i>PPAR Research</i> , 2021 , 2021, 6661181	4.3	1
63	Chronic AT blockade improves hyperglycemia by decreasing adipocyte inflammation and decreasing hepatic PCK1 and G6PC1 expression in obese rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021 , 321, E714-E727	6	0
62	Telmisartan Loaded Nanofibers Enhance Re-Endothelialization and Inhibit Neointimal Hyperplasia. <i>Pharmaceutics</i> , 2021 , 13,	6.4	0
61	The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?. <i>Pharmacology & Therapeutics</i> , 2021 , 108008	13.9	1
60	????????(????2004????). <i>Journal of JCS Cardiologists</i> , 2005 , 13, 109-114	0.1	
59	The antidiabetic effect of angiotensin II receptor antagonists. 2006 , 85-98		
58	Effect of Telmisartan on Blood Pressure and Renal Function of Psoriasis Patients on Cyclosporine MEPC. <i>Nishinohon Journal of Dermatology</i> , 2008 , 70, 204-207	0	
57	Effect of telmisartan on glycemic control in hemodialysis patients with type 2 diabetes. <i>Nihon Toseki Igakkai Zasshi</i> , 2009 , 42, 325-331	0.3	
56	Antihypertensive Drugs. 2009 , 198-234		
55	Vozmozhnosti telmisartana v ANGIO- i KARDioproteksii i uluchshenii pokazateley uglevodnogo obmena pri narushenii tolerantnosti k glyukoze. <i>Systemic Hypertension</i> , 2009 , 6, 47-50	1.6	

54	Relationship between Telmisartan Dose and Glycaemic Control in Japanese Patients with Type 2 Diabetes Mellitus and Hypertension. <i>Clinical Drug Investigation</i> , 2012 , 32, 577-582	3.2	
53	Differential Mechanisms of the Effect of Peroxisome Proliferator-Activated Receptor Gamma Agonists on Bleomycin-Induced Lung Fibrosis. <i>Open Journal of Respiratory Diseases</i> , 2013 , 03, 31-38	0.2	
52	Anti-inflammatory Effects of Telmisartan and Valsartan in Animal Model of Airways Inflammation. <i>Pharmacologia</i> , 2014 , 5, 149-154		
51	A PROSPECTIVE STUDY OF EFFECT OF TELMISARTAN (ANGIOTENSIN II RECEPTOR BLOCKER) ON METABOLIC PARAMETERS IN HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2016 , 3, 1635-1637	0	
50	Design of Novel Compounds with the Potential of Dual PPAR α Modulation for the Management of Metabolic Syndrome. <i>Nuclear Receptor Research</i> , 2017 , 4,	1.4	
49	Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application. <i>Systemic Hypertension</i> , 2017 , 14, 51-57	1.6	1
48	A PROSPECTIVE COMPARATIVE STUDY OF EFFECT OF TELMISARTAN PLUS DIET AND EXERCISE VERSUS TELMISARTAN AND METFORMIN ON METABOLIC PARAMETERS IN HYPERTENSIVE PATIENTS WITH THE METABOLIC SYNDROME. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2017 , 4, 4217-4220	0	
47	Evaluation of the Effect of Telmisartan on Gentamicin-Induced Nephrotoxicity in Rats. 2018 , 8, 76-82		
46	Acute toxic effects of telmisartan in spontaneously hypertensive rats fed a high fructose diet. <i>Physiological Research</i> , 2018 , 67, 851-856	2.1	
45	Changes of the diastolic function of left ventry in patients with arterial hypertension in the process of micardis treatment in the family doctor's conditions. <i>Modern Medical Technologies</i> , 2019 , 40, 45-47	0	
44	Drug delivery to rodents: how to deal with body mass and water intake fluctuations?. 2019 ,		1
43	Efficacy and Safety of Azilsartan Medoxomil and Telmisartan in Hypertensive Patients: A Randomized, Assessor-Blinded Study. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2020 , 8, 87-94	0.9	2
42	 2020 , 35-40	0	1
41	Effective strategies for the treatment of hypertension in postmenopausal obese women (case study). <i>Profilakticheskaya Meditsina</i> , 2020 , 23, 94	0.5	
40	Activation of AMPK by Telmisartan Decreases Basal and PDGF-stimulated VSMC Proliferation via Inhibiting the mTOR/p70S6K Signaling Axis. <i>Journal of Korean Medical Science</i> , 2020 , 35, e289	4.7	2
39	Telmisartan in the hypertension treatment: from pharmacological characteristics to clinical benefits. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020 , 19, 106-117	0.9	
38	DEVELOPMENT AND VALIDATION OF STABILITY INDICATING ANALYTICAL METHOD FOR SIMULTANEOUS ESTIMATION OF CILNIDIPINE, CHLORTHALIDONE AND TELMISARTAN IN BULK AND TABLET DOSAGE FORM. <i>Indian Drugs</i> , 2020 , 57, 51-55	0.2	0
37	Regulationsmechanismen des Renin-Angiotensin-Systems im kardiovaskulären System. 2006 , 377-407		

36	PPAR- δ Ligands and Diabetic Nephropathy. 2006 , 289-304		
35	Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 733-749		
34	Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?. <i>Vascular Health and Risk Management</i> , 2007 , 3, 265-78	4.4	2
33	Targeting cardiovascular protection: the concept of dual renin-angiotensin system control. <i>Medscape Journal of Medicine</i> , 2008 , 10 Suppl, S4		6
32	Angiotensin II receptor antagonists (AT-blockers, ARBs, sartans): similarities and differences. <i>Netherlands Heart Journal</i> , 2006 , 14, 381-387	2.2	8
31	Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. <i>Vascular Health and Risk Management</i> , 2009 , 5, 129-40	4.4	23
30	Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. <i>P and T</i> , 2011 , 36, 22-40	1.4	34
29	Effect of telmisartan in experimentally induced diabetes mellitus in rats. <i>International Journal of Health Sciences</i> , 2007 , 1, 249-56	1.1	4
28	Telmisartan counteracts TGF- β induced epithelial-to-mesenchymal transition via PPAR- δ in human proximal tubule epithelial cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2012 , 5, 522-194	1.9	19
27	An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan, Improves Insulin Resistance in KK-A(y) Diabetic Mice. <i>International Journal of Biomedical Science</i> , 2006 , 2, 333-6		
26	Effect of angiotensin II type 1 receptor blocker on renal function, arterial blood pressure and parathyroid hormone related protein over expression in cadmium induced nephrotoxicity in adult male rats. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2013 , 5, 109-19	3.4	4
25	Telmisartan protects 5/6 Nx rats against renal injury by enhancing nNOS-derived NO generation via regulation of PPAR δ signaling. <i>American Journal of Translational Research (discontinued)</i> , 2014 , 6, 517-27	3	9
24	The vasodilatory action of telmisartan on isolated mesenteric artery rings from rats. <i>Iranian Journal of Basic Medical Sciences</i> , 2015 , 18, 974-8	1.8	1
23	Effect of High-dose Telmisartan on the Prevention of Recurrent Atrial Fibrillation in Hypertensive Patients. <i>Journal of Atrial Fibrillation</i> , 2010 , 3, 289	0.8	0
22	Protective mechanisms of telmisartan against hepatic ischemia/reperfusion injury in rats may involve PPAR δ -induced TLR4/NF- κ B suppression.. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 145, 112374	7.5	1
21	Telmisartan Attenuates Kanamycin-Induced Ototoxicity in Rats. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
20	Telmisartan-Induced Cytotoxicity via G/M Phase Arrest in Renal Cell Carcinoma Cell Lines. <i>Biological and Pharmaceutical Bulletin</i> , 2021 , 44, 1878-1885	2.3	
19	Renin-Angiotensin-Aldosterone System. 2021 ,		0

18	BCAA-BCKA axis regulates WAT browning through acetylation of PRDM16.. <i>Nature Metabolism</i> , 2022 ,	14.6	4
17	Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction.. <i>European Journal of Pharmacology</i> , 2021 , 915, 174713	5.3	0
16	Drug repurposing: An emerging strategy in alleviating skin cancer.. <i>European Journal of Pharmacology</i> , 2022 , 175031	5.3	1
15	Angiotensin receptor blocker use is associated with upregulation of the memory-protective angiotensin type 4 receptor (AT4R) in the postmortem brains of individuals without cognitive impairment.		0
14	Improved lipogenesis gene expression in liver is associated with elevated plasma angiotensin 1-7 after AT1 receptor blockade in insulin-resistant OLETF rats. 2022 , 555, 111729		1
13	Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial. 2022 , 101, e30496		0
12	Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. 2022 , 136, 1347-1366		4
11	Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases. 13,		0
10	The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients. 2022 , 11, 6486		0
9	Efficacy and Safety of Angiotensin Receptor Blockers in a Pre-Clinical Model of Arrhythmogenic Cardiomyopathy. 2022 , 23, 13909		0
8	MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells. 2022 , 18, 305		0
7	Facile Synthesis of Benzimidazoles via N-Arylamidoxime Cyclization. 2022 , 7, 45678-45687		0
6	Behavioral and Proteomic Studies Reveal Methylglyoxal Activate Pathways Associated with Alzheimer's Disease. 2023 , 6, 65-75		1
5	Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease. 2023 , 24, 2345		0
4	The impact of peroxisome proliferator-activated receptor- α activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy.		0
3	Prenylated Chrysin Derivatives as Partial PPAR α Agonists with Adiponectin Secretion-Inducing Activity. 2023 , 14, 425-431		0
2	Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer's disease: A nationwide population-based cohort study. 15,		0
1	Efficacy and Safety of Coadministered Ezetimibe/Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial. 2023 , 12, 2377		0

